Logo
x

Search

Subscribe Now

 Approval

Celltrion’s Steqeyma (Biosimilar, Stelara) Receives the Health Canada’s Approval to Treat Various Chronic Inflammatory Conditions

Celltrion’s Steqeyma (Biosimilar, Stelara) Receives the Health Canada’s Approval to Treat Various Chronic Inflammatory Conditions

  • August 2, 2024
Insights+ Key Biosimilars Events of July 2024

Insights+ Key Biosimilars Events of July 2024

  • August 1, 2024
Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)

Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)

  • July 31, 2024
Bio-Thera Reports the EMA’s Approval of Avzivi (Biosimilar, Avastin) for Treating Multiple Indications

Bio-Thera Reports the EMA’s Approval of Avzivi (Biosimilar, Avastin) for Treating Multiple Indications

  • July 30, 2024
Roche’s Vabysmo (Faricimab) Receives the EC’s Approval to Treat Retinal Vein Occlusion (RVO)

Roche’s Vabysmo (Faricimab) Receives the EC’s Approval to Treat Retinal Vein Occlusion (RVO)

  • July 30, 2024
CStone Pharmaceuticals’s Cejemly (Sugemalimab) Receives the EC’s Approval to Treat Non-Small Cell Lung Cancer

CStone Pharmaceuticals’s Cejemly (Sugemalimab) Receives the EC’s Approval to Treat Non-Small Cell Lung Cancer

  • July 29, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.